This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q05.9 (Spina bifida, unspecified) | Special Copayment Reduction: V179 (rare disease) |
| B. Synonyms | Spina bifida, unspecified |
| C. Adult onset | Very low likelihood of first presenting in adulthood — spina bifida is a congenital neural tube defect that is mostly detected at birth or in the neonatal period. The 'unspecified' code is used when the lesion level is not specified or a specific level cannot be confirmed from documentation, and clinically the same diagnostic and treatment principles as other Q05.x codes apply. |
| 1. History | Spina bifida has been identified even in ancient Egyptian mummies, and advances in neurosurgery and preventive medicine in the 20th century have dramatically improved survival and prevention rates. |
| 2. Causes | Multifactorial causes including folate deficiency, antiepileptic drug exposure, maternal diabetes, MTHFR polymorphisms, and obesity. The same risk factors apply to the level-unspecified subtype. |
| 3. Genetics | Multifactorial inheritance. Multiple genes are involved, including MTHFR, VANGL1/2, and PAX3. Familial recurrence risk 3–5%. This is a level-unknown code, but the principles of genetic counseling are the same. |
| 4. General epidemiology | The incidence of all spina bifida (Q05) is 0.3–1.0 per 1,000 births. Q05.9 is often used for coding convenience and thus reflects the frequency of actually unclassified lesions. Special Copayment Reduction code V179 in Korea. |
| 5. Pathophysiology | Failure of posterior closure of the neural tube at around 4 weeks of gestation. The pathophysiology is the same even when the lesion level is unknown, and the degree of Chiari II malformation involvement differs depending on the presence of hydrocephalus. |
| 6. Symptoms | Depending on the lesion level, lower limb weakness/paralysis, bladder and rectal dysfunction, and sensory loss. Whether symptoms of raised intracranial pressure occur depends on the presence of hydrocephalus. |
| 7. Signs | Cyst or skin abnormality at the lesion site, abnormal lower limb reflexes, bladder distension, loss of rectal sensation. Imaging confirms a posterior spinal defect. |
| 8. Screening | MSAFP (15–20 weeks of gestation), detailed structural ultrasound (18–22 weeks of gestation), fetal MRI, amniotic fluid AFP/AChE. The same prenatal screening principles apply even for the level-unknown code. |
| 9. Diagnosis | After clarifying the level, extent, and degree of nerve damage by prenatal ultrasound and MRI, postnatal spine MRI, head imaging, urodynamic testing, and electrophysiological testing, reclassify under the appropriate Q05 code. |
| 10. Treatment | Surgical closure (open form), hydrocephalus management (shunt/ETV), CIC and anticholinergics (urological), bowel management, orthopedic correction of deformities, multidisciplinary rehabilitation. |
| 11. Prognosis | Determined by lesion level and degree of nerve damage. Early accurate level confirmation and specialized treatment are the key to improving prognosis. |
| 12. Prevention | Folate supplementation before and in early pregnancy, risk factor management, prenatal screening, genetic counseling. |
| 13. References | Adzick NS et al. NEJM 2011; Copp AJ et al. Lancet Neurol 2013, and 8 others |
Spina bifida is a congenital malformation that has existed alongside humankind, and posterior spinal defects have been identified in mummies from ancient Egypt (around 3000–1000 BC). The first systematic description in Western medicine dates back to 1641, when the Dutch physician Nicolaas Tulp described a case of myelomeningocele. In the 18th–19th centuries, European anatomical pathologists classified and named various anatomical variations of posterior vertebral arch defects, and the term spina bifida became established.
Spina bifida, unspecified (Q05.9) is a classification code in the ICD-10 coding system used when the lesion level is not recorded or cannot be confirmed. Clinically it should be classified at a specific level such as lumbar, sacral, or thoracic, but Q05.9 is assigned when level information is missing in initial clinical records, administrative coding, or review of old medical records. This code has the character of an unclassified code or a temporary code before the level is confirmed, and changing to a level-specific code after accurate clinical evaluation is recommended.
There are two turning points in the history of spina bifida. First, separately from Judith Graham Pool's discovery of cryoprecipitate in 1964, the introduction of intermittent clean catheterization (CIC) by Lapides et al. in 1972 revolutionized urological management of patients with spina bifida. Second, the results of the Medical Research Council (MRC) randomized controlled trial in 1991 showed that folic acid reduced recurrence of spina bifida by 72%, and folic acid supplementation for pregnant women became standardized in public health policy worldwide. The MOMS trial in 2011 proved the superiority of prenatal in utero spinal cord closure, which is currently performed at some tertiary centers. In Korea, the incidence of spina bifida has been decreasing since the 2000s with folic acid campaigns and strengthened prenatal screening, and patients with spina bifida receive the rare disease Special Copayment Reduction (V179) benefit.
The classification system for spina bifida has continued to evolve. In the past, classification centered on skin closure (open versus occult) and cyst contents (meningocele versus myelomeningocele), but now detailed classification according to spinal cord exposure, lesion level (cervical to sacral), presence of hydrocephalus and Chiari II malformation, and associated malformations is applied in clinical practice and research. The Q05.9 code is understood as a temporary code used before this detailed classification is completed or when information is missing.
The causes of spina bifida, unspecified (Q05.9) are the same as those of spina bifida with a specified level. Spina bifida is a congenital neural tube defect (NTD) that occurs when posterior closure of the embryonic neural tube is incomplete at about 28–30 days of gestation (post-fertilization). Even if the level of occurrence is unknown in coding, the etiological mechanism involves the same interaction of causal factors.
Folate deficiency: Folic acid, the water-soluble vitamin B9, is essential for cell division and DNA synthesis. Insufficient folate before and in early pregnancy impairs the neural tube closure process. Supplementation with folic acid 400–800 μg/day from 1 month before pregnancy to 3 months of pregnancy reduces the risk of NTD by about 50–70%. In countries that implemented national policies fortifying processed grains with folic acid, the incidence of spina bifida decreased by a further 20–35%.
Antiepileptic drugs (AED): Valproic acid inhibits expression of genes related to neural tube closure through histone deacetylase (HDAC) inhibition and interferes with folate metabolism, raising the risk of spina bifida to about 1–2%. Carbamazepine, phenytoin, and phenobarbital are also associated with a slight increase in risk. In pregnant women who must be treated for epilepsy, switching to relatively lower-risk drugs such as lamotrigine and levetiracetam is carefully considered.
Maternal diabetes: Pregestational diabetes and poor glycemic control raise the overall risk of congenital malformations, including spina bifida. Hyperglycemia increases reactive oxygen species generation and disturbs embryonic neural tube development. Strict glycemic management, keeping HbA1c below 6.5% from before pregnancy, is effective in reducing risk.
Obesity and other factors: Maternal obesity (BMI ≥30) is an independent risk factor for spina bifida. Body fat accumulation is known to affect folate absorption and metabolism and increase insulin resistance, worsening the embryonic developmental environment. Hyperthermia in early pregnancy (fever, sauna) can also induce a heat shock response that interferes with neural tube closure. Evidence is accumulating that micronutrient deficiencies (vitamin B12, inositol) also contribute to NTD risk.
Genetic factors: The MTHFR C677T polymorphism, variants in PCP pathway genes (VANGL1/2, CELSR1, SCRIB), and transcription factors (PAX3, ZIC2) are associated with spina bifida risk. With a family history, the recurrence risk rises to about 3–5%.
Spina bifida, unspecified follows a multifactorial pattern of inheritance genetically and has the same genetic structure as spina bifida with a specified level. It arises from the interaction of multiple genetic variants and environmental factors rather than a single gene defect.
MTHFR gene: The C677T TT homozygote reduces the activity of the enzyme that produces 5-MTHF by about 70%. When folate supplementation is sufficient, this risk can be offset, so the interaction with folate nutritional status is more important than the MTHFR variant itself. Clinically, MTHFR testing alone has limitations in predicting spina bifida risk, but with a family history it can be referred to when deciding on high-dose folic acid prescription.
PCP pathway genes: Rare loss-of-function variants of the VANGL1, VANGL2, CELSR1, and SCRIB genes have been found in families of patients with spina bifida. These genes are essential for neural tube closure through convergent extension cell movement. Penetrance is low in heterozygous carriers, so only some members of a family are affected. In a mouse model (Vangl2 Lp mutation), craniorachischisis is reproduced.
Chromosomal abnormalities and copy number variants: Spina bifida can appear as an associated malformation in trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome). The possible association of copy number variants (CNV), including microdeletions and duplications, with NTD is under study. At prenatal diagnosis, fetal karyotyping or chromosomal microarray (CMA) is performed together to exclude coexisting chromosomal abnormalities.
Genetic counseling and recurrence risk: The recurrence risk in families of patients with spina bifida is about 3–8 times higher than in the general population. The exact risk figure varies with lesion level, the number of affected individuals in the family, and the presence of genetic variants. In recurrence risk groups, preconception genetic counseling, high-dose folic acid supplementation, detailed prenatal ultrasound, and intensified follow-up with amniotic fluid testing are recommended. Even when the Q05.9 code is assigned, conducting additional evaluation to confirm the level during family counseling is advantageous for interpreting genetic risk.
The worldwide incidence of spina bifida (all Q05) is about 0.3–1.0 per 1,000 births, and varies greatly according to region, ethnicity, and folic acid supplementation policy. Spina bifida, unspecified (Q05.9) is a code with no specified level, so it reflects coding practice and data quality rather than actual incidence. This code is frequently used particularly in spina bifida registries, insurance claims, and legacy data review when level information is missing.
The main determinant of spina bifida incidence is folic acid supplementation and fortification policy. In the United States, the incidence of spina bifida decreased by about 23–35% after grain folic acid fortification in 1998. Similar decreases have been reported in Canada, Chile, Wales in the United Kingdom, and elsewhere. In countries that have not implemented folic acid fortification, differences in incidence appear according to the rate of voluntary folic acid intake among pregnant women. In East Asia (Korea, Japan, China), the incidence of spina bifida is relatively low even without folic acid fortification owing to dietary characteristics, but an additional reduction is expected if a fortification policy is introduced.
Status in Korea: According to Health Insurance Review & Assessment Service (HIRA) and national congenital anomaly registry data, the annual birth incidence of spina bifida (all Q05) is about 1.0–2.5 per 10,000 births, with a decreasing trend since the 2000s. Patients registered for rare disease Special Copayment Reduction (V179) are patients with neural tube defects including spina bifida, and receive reduced copayment benefits for 5 years. For those registered with Q05.9, reconfirming the level and changing to a level-specific code is advantageous for accurate clinical management. In the sex distribution of all spina bifida patients, the incidence tends to be slightly higher in girls, but this difference is small and not consistent across studies.
Socioeconomic factors also affect incidence. The incidence is higher in low-income groups with low access to prenatal care and in nutritionally deficient groups, and nonspecific codes such as Q05.9 may be used more commonly in health systems where the quality of prenatal ultrasound screening is low. Therefore, in epidemiological studies the frequency of Q05.9 can also be interpreted as an indicator reflecting the coding accuracy of the health system.
The pathophysiology of spina bifida, unspecified (Q05.9) is fundamentally the same as that of spina bifida with a specified level. It is a neural tube defect caused by incomplete posterior closure of the embryonic neural tube at about 28–30 days of gestation (post-fertilization; about 6 weeks from the last menstrual period). Depending on the lesion level, defects of primary neurulation (lumbar and above) and secondary neurulation (sacral and coccygeal levels) are involved respectively.
Primary neurulation defect: At 18–28 days of gestation, the neural plate folds to form neural folds and closes sequentially from the cranial to the caudal direction. When a defect occurs in this closure process at the lumbar level, the posterior vertebral arch and the spinal cord and meninges do not close. Folate deficiency, defective PCP signaling, and mitochondrial dysfunction impair this closure process.
Secondary neurulation defect: The spinal cord at the sacral and coccygeal levels forms through cavitation of the caudal cell mass. In this process, hyperglycemic toxicity from maternal diabetes, abnormal WNT/BMP signaling, and inositol deficiency are studied as causing defects.
Differences in mechanism by presence of hydrocephalus: The Q05.9 code does not specify whether hydrocephalus is present. The subtype with hydrocephalus adds the mechanism of posterior fossa and cerebrospinal fluid circulation disorder due to Chiari II malformation, whereas this mechanism is absent or mild in the subtype without hydrocephalus. When evaluating a patient entered under code Q05.9, confirming the presence of hydrocephalus is important for clinical management.
Mechanistic differences between open and occult spina bifida: In open myelomeningocele, the spinal cord and meninges are exposed outside the skin and directly exposed to amniotic fluid and infectious agents, causing secondary nerve damage. In occult spina bifida (skin-closed form), only the primary defect exists and there is no secondary damage. This difference explains the difference in neurological prognosis between the two subtypes. Prenatal in utero closure is based on the principle of blocking secondary nerve damage in open lesions.
The clinical symptoms of spina bifida, unspecified (Q05.9) are determined by the actual lesion level and degree of nerve damage. The Q05.9 code means that the level is not specified, not that the nature of the symptoms differs. In clinical practice, the lesion level must be confirmed when evaluating a patient and symptoms interpreted by level.
Motor dysfunction: Lower limb weakness or paralysis below the lesion level is the main symptom. At the thoracic level, complete lower limb paralysis occurs; at the lumbar level, partial paralysis may allow assisted walking; and at the sacral level, lower limb strength is mostly preserved. Equinovarus foot, hip dislocation, and knee flexion contracture due to lower limb muscle imbalance accompany.
Sensory dysfunction: Touch, pain, temperature sense, and proprioception are lost in dermatomes below the lesion level. Areas of sensory loss are at risk for pressure ulcers, and wounds commonly worsen because of inability to perceive pain. Regular skin examination and education on preventing pressure injury are essential.
Bladder and rectal dysfunction: Neurogenic bladder and neurogenic bowel occur in most patients with spina bifida. In the bladder, increased residual urine, urinary incontinence, and recurrent urinary tract infection occur. In the rectum, fecal incontinence or chronic constipation occurs. These dysfunctions are the problems that most affect social participation and quality of life.
Hydrocephalus-related symptoms: When hydrocephalus accompanies (subtypes corresponding to Q05.0–Q05.6), headache, vomiting, papilledema, the setting-sun sign, and altered consciousness may occur due to raised intracranial pressure. Rapid deterioration occurs with shunt malfunction, so immediate evaluation is needed. In patients entered under the Q05.9 code as well, confirming the presence of hydrocephalus is the priority.
Spinal deformity: Scoliosis, kyphosis, and lumbar hyperlordosis progress with growth and, in severe cases, affect cardiopulmonary function and sitting stability. Regular radiographic follow-up and orthopedic consultation are needed. If tethered cord syndrome develops, existing symptoms worsen or new neurological deficits appear.
The physical signs of spina bifida, unspecified vary according to lesion level, open/occult type, and presence of hydrocephalus. When first seeing a patient with the Q05.9 code, a whole-body physical examination and imaging studies to confirm the lesion level are essential.
Back and skin findings: In open myelomeningocele, a cystic lesion is observed at the posterior midline of the back. In occult spina bifida, midline skin abnormalities (dermal sinus, lipoma, hemangioma, hair tuft, dimple) serve as external markers of an internal spinal cord lesion. Confirm the size, location, and contents of the cyst and assess skin integrity.
Neurological signs: Systematically assess lower limb muscle strength grade by lesion level (MRC scale), sensory loss dermatomes, deep tendon reflexes (patellar and Achilles reflexes), and the presence of the anal reflex. Confirmation of upper limb and bulbar function differentiates cervical level or complicating hydrocephalus. The neurological level is determined according to the ASIA (American Spinal Injury Association) standards.
Urological signs: Palpate for bladder distension, measure residual urine, and check for hydronephrosis by renal ultrasound. Urodynamic testing classifies the bladder type (overactive, underactive, mixed) to establish the treatment plan.
Intracranial signs: To assess for hydrocephalus, check bulging anterior fontanelle, rate of head circumference increase, and the setting-sun sign in neonates, and perform head ultrasound or MRI. Cerebellar tonsillar descent (Chiari II malformation) findings may be associated with brainstem compression symptoms (dysphagia, apnea, vocal cord paralysis).
Imaging findings: Spine MRI is the standard test for evaluating lesion level, extent, tethered cord, and Chiari malformation. In patients entered under Q05.9, reclassify under the appropriate Q05.x code according to the MRI results. Head MRI evaluates hydrocephalus, ventricular size, and Chiari II malformation. X-ray is used for basic evaluation of posterior spinal defects and spinal deformity.
Prenatal screening for spina bifida, unspecified (Q05.9) follows the same standard prenatal screening system as other spina bifida subtypes. Although the level is not specified in the code, the actual screening methods and diagnostic process are the same.
Maternal serum AFP (MSAFP): Measured at 15–20 weeks of gestation; in open NTD, maternal serum AFP rises to 2.5 MoM or more of the normal median. Sensitivity is about 80–85% for open lesions. It is performed as part of a double marker (MSAFP + ultrasound) or quadruple marker (quad screen) test.
Fetal detailed structural ultrasound: On detailed ultrasound at 18–22 weeks of gestation, check for posterior vertebral arch defect, skin defect, and cyst, and assess intracranial findings (ventricular size, cerebellar shape, frontal bone shape). Among ultrasound findings, the lemon sign (frontal bone indentation), banana sign (flattening of the cerebellum), and ventricular dilatation suggest accompanying Chiari II. The lesion level is estimated by systematically scanning all spinal levels. If level confirmation is incomplete, the Q05.9 code is assigned temporarily.
Fetal MRI: Performed as a complementary test when an abnormality is suspected on ultrasound but the level is difficult to determine, or when an occult lesion is suspected. MRI is superior to ultrasound for accurate level confirmation and evaluation of Chiari malformation and ventricular size. Performing it after 24 weeks of gestation makes fetal structures easier to interpret.
Amniotic fluid testing: Measurement of amniotic fluid AFP and AChE is used to confirm open NTD. Fetal karyotyping or CMA is performed simultaneously to exclude coexisting chromosomal abnormalities. Performed at 15–20 weeks of gestation.
Intensified follow-up of high-risk groups: In patients with a family history of spina bifida, a previous affected child, valproic acid use, or maternal diabetes, perform preconception genetic counseling, high-dose folic acid (5 mg/day), intensified prenatal ultrasound and MRI, and amniotic fluid testing.
The diagnosis of spina bifida, unspecified (Q05.9) is understood as a process of detailed evaluation to clinically compensate for the unknown level at the initial coding stage. In actual clinical practice, the principle is to confirm the lesion level as early as possible, reclassify under the appropriate Q05.x code, and establish a treatment plan suited to the level.
Spine MRI to confirm the lesion level: After birth, perform whole-spine MRI (cervical to coccygeal) to accurately measure the upper and lower levels of the posterior defect. Assess the form of the lesion (meningocele, myelomeningocele, lipomyelomeningocele, occult), spinal cord exposure, tethered cord, and presence of syringomyelia. Based on these results, reclassify under the appropriate code among Q05.1–Q05.8.
Head imaging: Assess the presence of hydrocephalus (lateral ventricular dilatation) and the presence and degree of Chiari II malformation by head MRI or ultrasound. Whether hydrocephalus accompanies is the classification criterion for Q05.0–Q05.6 (with hydrocephalus) or Q05.7–Q05.9 (without hydrocephalus).
Neurological evaluation: Measure the motor level and sensory level according to the ASIA classification and check concordance with the lesion level. Collect baseline electrophysiological data (EMG, SSEP, MEP) in advance for intraoperative neuromonitoring (IONM).
Urological evaluation: From the neonatal period, classify bladder function by urodynamic testing and assess the upper urinary tract with renal ultrasound and VCUG. Check for baseline urinary tract infection with urinalysis and urine culture.
Other tests: Fetal karyotype or CMA (performed after birth if not done prenatally), hearing and vision function evaluation (to confirm Chiari II-related cranial nerve function), and echocardiography (to exclude associated congenital heart malformation) are performed as needed. Cognitive and developmental screening with developmental assessment tools (Bayley, WPPSI) is important during follow-up.
Treatment of spina bifida, unspecified (Q05.9) follows the standard treatment of the corresponding subtype once the level is confirmed. The general treatment principles apply in common to all spina bifida subtypes.
Surgical closure: For open lesions, perform neurosurgical spinal cord closure within 24–72 hours after birth. The cyst and meninges are sutured in layers to protect the spinal cord and prevent meningitis. For occult lesions, perform resection of lipomyelomeningocele, release of a thick filum terminale, and closure of dermal sinus. Prenatal in utero closure is considered at specialized tertiary centers when eligibility criteria are met.
Hydrocephalus management: When accompanying hydrocephalus is confirmed, perform ventriculoperitoneal shunt (VP shunt) or endoscopic third ventriculostomy (ETV). Shunt malfunction (obstruction, infection, overdrainage) requires immediate neurosurgical evaluation.
Urological treatment: CIC, anticholinergics, intravesical botulinum toxin injection, bladder augmentation, artificial urinary sphincter implantation, and creation of a Mitrofanoff catheterizable channel are applied stepwise according to urodynamic results and the principle of upper urinary tract protection. Preservation of renal function is monitored with regular renal function tests (eGFR, renal scan).
Bowel management: A regular bowel program (suppositories, enemas, high-fiber diet, adequate hydration) and creation of an antegrade enema route by the MACE procedure are used to establish stool control. Biofeedback therapy may be helpful in patients with residual anal sensation.
Orthopedic treatment and rehabilitation: Prescribe lower limb orthoses suited to the lesion level, correct clubfoot, stabilize the hip, and correct spinal deformity, and support achievement of maximal function with physical therapy, occupational therapy, and psychosocial support. Preparation for transition to adult care (transition care) begins in adolescence to promote a smooth transfer from pediatric-centered to adult-centered care.
The prognosis of spina bifida, unspecified (Q05.9) is determined by the actual lesion level and degree of nerve damage, the presence of accompanying hydrocephalus, and access to treatment. The lower the level (toward the sacral), the more lower limb function and cognitive function are preserved and the better the prognosis.
Overall, the life expectancy of patients with spina bifida has improved greatly with modern multidisciplinary treatment. The survival rate of appropriately managed patients with spina bifida to adulthood is about 85–90%, and the main causes of death are renal failure, sepsis (pressure ulcers, urinary tract infection), and raised intracranial pressure (shunt malfunction). Early multidisciplinary treatment, aggressive management of neurogenic bladder, preservation of renal function, and early release of tethered cord are the key to improving prognosis. The possibility of schooling, employment, independent living, and social participation varies greatly between individuals depending on lesion level and access to treatment. In particular, substantial quality of life and social participation are possible in lower-level lesions without hydrocephalus. Appropriate prognostic counseling should be given to patients classified as Q05.9 after reconfirming the level.
Prevention strategies for spina bifida, unspecified follow the same principles as other spina bifida subtypes.
Primary prevention: Folic acid 400–800 μg/day is recommended for all women who may become pregnant, from 1 month before pregnancy to 3 months of pregnancy. In high-risk groups (previous affected child, family history, valproic acid use, maternal diabetes, obesity), high-dose folic acid (5 mg/day) is prescribed. This includes preconception control of maternal diabetes (HbA1c <6.5%), obesity management, and consideration of alternatives to high-risk antiepileptic drugs. National introduction of folic acid-fortified food policies is effective for population-level prevention.
Secondary prevention: Include MSAFP at 15–20 weeks of gestation and detailed structural ultrasound at 18–22 weeks of gestation in standard prenatal care. If abnormal findings are present, confirm with fetal MRI and amniotic fluid AFP/AChE, and after confirming the level, reclassify under the appropriate Q05.x code. When the eligibility criteria for prenatal in utero closure are met, refer early to a specialized center.
Tertiary prevention: Register immediately after birth in a multidisciplinary spina bifida clinic, and perform early management of neurogenic bladder (starting CIC), surveillance for signs of tethered cord, and regular renal function, spine, and head imaging follow-up. Education on skin protection, pressure ulcer prevention, psychosocial support, and planning for transition to adult care are included in long-term management.